{"id":11034,"date":"2026-10-27T19:08:03","date_gmt":"2026-10-27T23:08:03","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=11034"},"modified":"2026-10-27T23:33:48","modified_gmt":"2026-10-28T03:33:48","slug":"medicure-finishes-at-new-7-year-closing-high-double-digits-will-be-here-shortly","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/medicure-finishes-at-new-7-year-closing-high-double-digits-will-be-here-shortly\/","title":{"rendered":"Medicure Finishes at New 7-Year Closing High of $4.44: Double Digits Will Be Here Shortly"},"content":{"rendered":"\n
\n\n

\n Medicure (TSXV: MPH) gained by 0.91%<\/span><\/strong> today to a\n new 7-year closing high<\/strong><\/span> of\n $4.44 per share<\/strong> and will be\n double digits<\/strong><\/span> shortly that is a\n 100% fact<\/strong><\/span>.\n Either research MPH<\/strong> right now or you will\n pay a much higher<\/span> price<\/strong> later:\n <\/p>\n\n

\n \"Medicure\n <\/p>\n\n

\n According to the CBO<\/strong>, out of every\n 100 drugs that enter Phase 1 trials<\/strong>, only\n 20 make it to Phase 3 trials<\/strong> and\n 12 get approved<\/span><\/strong>,\n but 60%<\/span> of drugs in Phase 3 trials get\n approved<\/span><\/strong>.\n <\/p>\n\n

\n Almost all US$30 million market cap biotech companies<\/strong> are in\n Phase 1 trials<\/strong> with a\n 12% chance of approval<\/strong><\/span>.\n MPH<\/strong> is in Phase 3 trials<\/strong> with a\n 60% chance of approval<\/strong><\/span>.\n <\/p>\n\n

\n If MPH<\/strong> gets\n approval<\/strong><\/span>, they\n receive<\/strong><\/span> an\n FDA Priority Review Voucher<\/strong> that can be sold, with recent transactions\n for them all selling for\n more than<\/span> US$200 million<\/strong>.\n <\/p>\n\n

\n MPH<\/strong> should at least be worth\n US$120 million<\/strong><\/span>\n right now<\/strong><\/span>, if not more.\n <\/p>\n\n

\n We think the odds of MPH<\/strong> getting\n approval<\/strong><\/span> for\n MC-1<\/strong> are actually\n more than 90%<\/strong><\/span>.\n MPH’s lead investigator, Dr. Phillip Pearl<\/strong>, is the\n #1 top guy in the world<\/strong><\/span>,\n Boston Children’s Hospital<\/strong> is the\n #1 best in the world<\/strong><\/span>,\n and Harvard Medical School<\/strong> is the\n #1 best in the world<\/strong><\/span>.\n \n Click here to see<\/a> him talk about how MPH’s drug works!<\/strong>\n <\/p>\n\n

\n \n Past performance is not indicative of future results.\n NIA is not an investment advisor and does not provide investment advice.\n Always do your own research and make your own investment decisions.\n NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares.\n This communication is for informational and educational purposes only.\n <\/em>\n <\/p>\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Medicure (TSXV: MPH) gained by 0.91% today to a new 7-year closing high of $4.44 per share and will be double digits shortly that is a 100% fact. Either research MPH right now or you will pay a much higher price later: According to the CBO, out of every 100 drugs that enter Phase 1 […]<\/p>\n","protected":false},"author":1,"featured_media":11036,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[365,414],"class_list":["post-11034","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotech","tag-mph"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=11034"}],"version-history":[{"count":3,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11034\/revisions"}],"predecessor-version":[{"id":11042,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11034\/revisions\/11042"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/11036"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=11034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=11034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=11034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}